Cargando…
Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial
PURPOSE: The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901417/ https://www.ncbi.nlm.nih.gov/pubmed/35264863 http://dx.doi.org/10.2147/DMSO.S350518 |
_version_ | 1784664366379958272 |
---|---|
author | Teragawa, Hiroki Morimoto, Takeshi Fujii, Yuichi Ueda, Tomohiro Sakuma, Mio Shimabukuro, Michio Arasaki, Osamu Node, Koichi Nomiyama, Takashi Ueda, Shinichiro |
author_facet | Teragawa, Hiroki Morimoto, Takeshi Fujii, Yuichi Ueda, Tomohiro Sakuma, Mio Shimabukuro, Michio Arasaki, Osamu Node, Koichi Nomiyama, Takashi Ueda, Shinichiro |
author_sort | Teragawa, Hiroki |
collection | PubMed |
description | PURPOSE: The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial. PATIENTS AND METHODS: We measured the estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, and blood pressure (BP). RESULTS: No significant differences were found in baseline eGFR and UACR between the two groups. The eGFR levels were significantly decreased in both groups; however, the UACR level was unchanged in the ANA group but elevated in the SITA group, although the difference did not reach significance between the two groups. The difference in eGFR was affected by the differences in HbA1c level and BP, and the difference in the UACR was affected by the differences in LDL-C level and BP, which were reduced only in the ANA group. CONCLUSION: These findings imply that the effects of DPP-4 inhibitors on renal function, especially on UACR, may be different between the types of DPP-4 inhibitors. |
format | Online Article Text |
id | pubmed-8901417 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-89014172022-03-08 Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial Teragawa, Hiroki Morimoto, Takeshi Fujii, Yuichi Ueda, Tomohiro Sakuma, Mio Shimabukuro, Michio Arasaki, Osamu Node, Koichi Nomiyama, Takashi Ueda, Shinichiro Diabetes Metab Syndr Obes Original Research PURPOSE: The effects of two types of dipeptidyl peptidase-4 (DPP-4) inhibitors on renal function remain unclear. Thus, we investigated the effect of anagliptin (ANA) and sitagliptin (SITA) on renal function in patients with type 2 diabetes who participated in the randomized evaluation of ANA versus SITA on low-density lipoprotein-cholesterol (LDL-C) in diabetes (REASON) trial. PATIENTS AND METHODS: We measured the estimated glomerular filtration rate (eGFR) and urinary albumin–creatinine ratio (UACR) before and after the REASON trial. ANA 200 mg/day was administered to 177 patients for 52 weeks, while SITA 50 mg/day was given to 176 patients. We investigated the relationship between differences in renal function and differences in hemoglobin A1c (HbA1c) levels, LDL-C levels, and blood pressure (BP). RESULTS: No significant differences were found in baseline eGFR and UACR between the two groups. The eGFR levels were significantly decreased in both groups; however, the UACR level was unchanged in the ANA group but elevated in the SITA group, although the difference did not reach significance between the two groups. The difference in eGFR was affected by the differences in HbA1c level and BP, and the difference in the UACR was affected by the differences in LDL-C level and BP, which were reduced only in the ANA group. CONCLUSION: These findings imply that the effects of DPP-4 inhibitors on renal function, especially on UACR, may be different between the types of DPP-4 inhibitors. Dove 2022-03-03 /pmc/articles/PMC8901417/ /pubmed/35264863 http://dx.doi.org/10.2147/DMSO.S350518 Text en © 2022 Teragawa et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Teragawa, Hiroki Morimoto, Takeshi Fujii, Yuichi Ueda, Tomohiro Sakuma, Mio Shimabukuro, Michio Arasaki, Osamu Node, Koichi Nomiyama, Takashi Ueda, Shinichiro Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title_full | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title_fullStr | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title_full_unstemmed | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title_short | Effect of Anagliptin versus Sitagliptin on Renal Function: Subanalyzes from the REASON Trial |
title_sort | effect of anagliptin versus sitagliptin on renal function: subanalyzes from the reason trial |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8901417/ https://www.ncbi.nlm.nih.gov/pubmed/35264863 http://dx.doi.org/10.2147/DMSO.S350518 |
work_keys_str_mv | AT teragawahiroki effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT morimototakeshi effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT fujiiyuichi effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT uedatomohiro effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT sakumamio effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT shimabukuromichio effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT arasakiosamu effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT nodekoichi effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT nomiyamatakashi effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial AT uedashinichiro effectofanagliptinversussitagliptinonrenalfunctionsubanalyzesfromthereasontrial |